Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 8/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 4/20 | 0.40 |
| ▸ | KDM4A | O75164 | 2/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.40 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4155263 | 0.88 | AOC3 (0.43) | PTGESAOC3ABHD6 | |
| SCHEMBL3667316 | 0.86 | PDCD1 (0.39) | PRMT6AOC3 | |
| SCHEMBL3724941 | 0.86 | KDM4A (0.40) | KDM4AKDM4CHDAC1 | |
| SCHEMBL4151005 | 0.84 | PRMT6 (0.37) | PRMT6AOC3BCHEACHE | |
| SCHEMBL3724516 | 0.83 | AOC3 (0.41) | PRMT6PTGESAOC3ABHD6 | |
| SCHEMBL3724410 | 0.82 | FFAR1 (0.48) | FFAR1 | |
| SCHEMBL3667382 | 0.80 | HTR7 (0.43) | PRMT6AOC3ABHD6 | |
| SCHEMBL3663779 | 0.79 | FFAR1 (0.42) | PRMT6AOC3KDM4CFFAR1HDAC1 | |
| SCHEMBL3730365 | 0.79 | GRIN2D (0.47) | PRMT6 | |
| SCHEMBL3666969 | 0.79 | VSIR (0.43) | PRMT6AOC3KDM4CFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101970435-B | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG | 2014-07-02 | — | — | CN | claimed |
| CN-101970435-A | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG | 2011-02-09 | — | — | CN | claimed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | PRMT6 1956/4885PTGES 2577/4885AOC3 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.